Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

Abstract

Highlights • Bone remodeling is disrupted in metastatic disease, affecting > 70% of mCRPC men.• In metastatic disease, abnormal levels of specific BTMs are released.• We prospectively measured four BTMs markers in chemotherapy-naïve mCRPC men on AAP therapy.• AAP seems to act on the microenvironment of metastatic but not of normal bone.• This action likely contributes to the antitumoral activity of AAP.